

Synthesis, Crystal Structure and Hydrogen-bonding Patterns in Rac-N-acetyl-2-thiohydantoin-leucine

Gerzon E. Delgado*, María E. Sulbaran, Asiloé J. Mora

Laboratorio de Cristalografía, Departamento de Química Facultad de Ciencias, Universidad de Los Andes, Mérida 5101, Venezuela

Abstract In this work we present the synthesis and X-ray single crystal structural characterization of the heterocyclic compound rac-N-acetyl-2-thiohydantoin-leucine. This material crystallize in the triclinic system with space group P-1 ($N^{\circ}2$), $Z=4$, with two independent molecules in the unit asymmetric. The crystal packing is governed by N-H...O hydrogen bond-type intermolecular interactions, forming in finite one-dimensional chains with graph-set motif C(6).

Keywords Thiohydantoin, Crystal Structure, Hydrogen Bonding

1. Introduction

Thiohydantoin and hydantoin are five-member heterocyclic system with a very reactive nucleus, which provides four possible points of diversity. Both heterocycles represent significant building blocks for combinatorial chemistry libraries[1-4]. The biological activities of hydantoin and 2-thiohydantoin derivatives has been known for a long time, and are responsible for a wide variety of biological behaviour[5], due principally to its wide range of therapeutic properties. For instance, several applications have been reported for hydantoin: antiarrhythmic and antihypertensive[6-7], antiviral[8], antineoplastic[9], antitumoral[10] and anticonvulsant agents[11-12]. The best known hydantoin, phenytoin, is the most widely used antiepileptic drug[13]. Thiohydantoin is known for their uses as hypolipidemic[14], antimutagenic[15] and anticarcinogenic agents[16]. In addition, both heterocyclic compounds are used as herbicides[17] and fungicides agents[18]. Recently, there has been interest in the search of new synthetic routes for the preparation of these type of compounds, via solution or solid state reactions[19-21].


We are interested in N-carbamoyl, hydantoin and thiohydantoin derivatives of α -amino acids[22-28], and report here the structure of the N-acetylthiohydantoin derivative of the α -amino acid L-leucine.

2. Experimental

2.1. Synthesis

The title compound was synthesized from L-leucine using a modified methodology previously reported[18-19]. L-leucine (1000 mg, 7.6 mmol) and NH_4SCN (580.3 mg, 7.6 mmol) was dissolved in a 9 ml acetic anhydride - 1 ml acetic acid mixture and transferred in a 25 ml round-bottom flask. The mixture was warmed, with agitation, to 363 K over a period of 30 min. The resulting solution was cooled in a ice/water mixture and stored in a freezer overnight. The resulting white solid was filtered off and washed with cool water (m.p. 404-405 K). Crystal of (I) suitable for X-ray diffraction analysis were obtained by slow evaporation of a 1:1 ethanol-methanol solution.

RMN^1H (400 MHz, DMSO-d_6) $\delta=12.66$ (H3, s), 4.71 (H5, d), 2.70 (H7, s), 1.76 (H8, H9, m), 0.85 (H10, H11, d). RMN^{13}C (100.6 MHz, DMSO-d_6) $\delta=182.5$ (C2), 173.5 (C4), 169.7 (C6), 61.3 (C5), 38.1 (C8), 27.3 (C7), 23.7 (C9), 23.1 (C10), 21.9 (C11).



Scheme 1. Synthesis of rac-N-acetyl-2-thiohydantoin-leucine

2.2. X-Ray Crystallography

Colorless rectangular crystal (0.3, 0.3, 0.1 mm) was used for data collection. Diffraction data were collected at 298(2) K by ω -2 θ scan technique on a Siemens P4 four-circle diffractometer[29] equipped with graphite monochromatized $\text{CuK}\alpha$ radiation ($\lambda = 1.54178 \text{ \AA}$). The data were corrected for Lorentz-polarization and absorption effects[29]. Three standard reflections were monitored every 100 reflections (intensity decay: none). The structure was solved by direct

* Corresponding author:

gerzon@ula.ve (Gerzon E. Delgado)

Published online at <http://journal.sapub.org/ijmc>

Copyright © 2013 Scientific & Academic Publishing. All Rights Reserved

methods using the SHELXS97 program[30] and refined by a full-matrix least-squares calculation on F^2 using SHELXL97[30].

Table 1. Crystal data, data collection and structure refinement

Chemical formula	C ₉ H ₁₄ N ₂ O ₂ S
Formula weight	214.28
Crystal system	Triclinic
Space group	P-1
a(Å)	7.1855(4)
b(Å)	9.7300(4)
c(Å)	16.442(1)
α (°)	101.13(1)
β (°)	94.00(1)
γ (°)	90.49(1)
V(Å ³)	1125.0(1)
Z	4
dx (g cm ⁻³)	1.265
F(000)	456
μ (mm ⁻¹)	0.27
θ range (°)	2.8-69.1
hkl range	-1 ≤ h ≤ 8, -11 ≤ k ≤ 11, -18 ≤ l ≤ 19
Reflections	
Collected	4921
Unique (Rint)	3991 (0.088)
With I > 2 σ (I)	3003
Refinement method	Full-matrix least-squares on F ²
Number of parameters	260
R(F ²)[I > 2 σ (I)]	0.0782
wR(F ²)[I > 2 σ (I)]	0.1998
Goodness of fit on F ²	1.11
Max/min $\Delta\rho$ (e Å ⁻³)	0.73/-0.71

Table 2. Selected geometrical parameters (Å, °)

Molecule A		Molecule B	
S2-C2	1.6340(3)	S21-C21	1.6480(3)
O4-C4	1.2050(4)	O41-C41	1.2070(4)
O6-C6	1.2130(4)	O61-C61	1.2190(4)
N1-C2	1.3860(4)	N11-C21	1.3860(4)
N3-C2	1.3770(4)	N31-C21	1.3650(4)
N3-C4	1.3700(4)	N31-C41	1.3780(4)
S2-C2-N1	131.5(2)	S21-C21-N11	130.8(2)
S2-C2-N3	122.8(2)	S21-C21-N31	122.6(2)
O4-C4-N3	125.5(3)	O41-C41-N31	125.8(3)
O4-C4-C5	128.2(3)	O41-C41-C51	127.9(3)
C6-N1-C2-S2	4.10(5)	C61-N11-C21-S21	-6.90(5)
C4-N3-C2-S2	-174.80(2)	C41-N31-C21-S21	176.50(2)

Table 3. Hydrogen bonds geometry (Å, °). (D-donor; A-acceptor; H-hydrogen)

D--H...A	D—H	H...A	D...A	D--H...A
N3—H3...O6 ⁽ⁱ⁾	0.860(i)	1.980	2.825(3)	166.6
N3—H31...O61 ⁽ⁱⁱ⁾	0.860(ii)	1.990	2.834(3)	167.7

Symmetry codes: (i) 1+x, y, z, (ii) -1+x, y, z

All H atoms were placed at calculated positions and treated using the riding model, with C-H distances of 0.97-0.98 Å, and N-H distances of 0.86 Å. The Uiso(H) parameters were fixed at 1.2Ueq(C, N) and 1.5Ueq(methyls)

Crystallographic data for the structure reported here have been deposited with the Cambridge Crystallographic Data Centre (Deposition No. CCDC-860694). The data can be obtained free of charge via <http://www.ccdc.cam.ac.uk/per/categ.cgi> (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK; e-mail: deposit@ccdc.cam.ac.uk).

Molecular diagrams were generated using Diamond[31]. All geometrical calculations were done using the program Platon[32]. Table 1 summarizes the crystal data, intensity data collection and refinement details for the title compound. Selected geometrical parameters are presented in Table 2. Table 3 shows the hydrogen bonding geometry for the title compound.

3. Results and Discussion

N-acetyl-thiohydantoin-L-leucine crystallizes with two independent molecules in the asymmetric unit, in a centrosymmetric space group, which implies that L-leucine suffered an amino acid racemization produced by the use of acetic acid in the synthesis[33]. Figure 1 shows the atom labeling and molecular conformation of the two independent molecules of the title compound in the asymmetric unit.

All bond distances and angles are normal[34] and are in agreement with the average values found in 31 entries with 36 thiohydantoin ring fragments, searched in the Cambridge Structural Database (CSD, version 5.33; Feb, 2012) with N1 and N3 unsubstituted and sp³ hybridization at C5. The thiohydantoin ring, in both molecules, is essentially planar with a maximum deviations of 0.034(3) Å in C4 and -0.037(3) Å in C4, in molecule A and 0.039(3) Å in C41 and -0.038(3) Å in C51, for molecule B.

The S2-C2-N1 bond angles are greater than S2-C2-N3 angles in both molecules. This difference is also observed in the only three 2-N-acetyl thiohydantoin compounds reported in the CSD; KOMGUO[35] with angle values 130.6° and 123.4°, NIFHIT[36] with angles 132.0° and 121.9°, and DIKWAW[28] with angles 132.2°-131.2° and 125.8°-119.0°. The average values for the same angle in the 36 fragments searched above are 127.7° and 125.2°, respectively.

The S2-C2 and S21-C21 distance values, see Table 2, agree with the average value of 1.646 Å found for the 36 fragments search in the CSD, with minimal and maximum reported values of 1.519 and 1.696 Å, respectively.

The molecular structure and crystal packing of the title compound is stabilized by intermolecular N3--H3...O4 (x, 1/2 - y, 1/2 + z) hydrogen bonds (Table 3), forming infinite one-dimensional chains that run along[100] direction, which can be described in graph-set notation as C(6)[37] (Figure 2).




Figure 1. Asymmetric unit with anisotropic ellipsoid representations, together with atom labeling scheme. The ellipsoids are drawn at 25% probability level, hydrogen atoms are depicted as spheres with arbitrary radii




Figure 2. Packing view of 1. Intermolecular hydrogen bonds, N-H...O and O-H...O, are indicated by dashed lines. H atoms not involved in hydrogen bonding have been omitted for clarity

4. Conclusions

The thiohydantoin derivative *rac*-N-acetyl-2-thiohydantoin-leucine was synthesized and characterized by NMR spectroscopy. This material crystallize in the triclinic system with space group P-1 ($N^{\circ}2$), $Z=4$, with two independent molecules in the unit asymmetric. In the crystal structure, the molecules are linked by N---H...O hydrogen bonds, forming infinite one-dimensional zigzag chains, running along [100] direction, with C(6) graph-set motif.

ACKNOWLEDGEMENTS

This work was supported by CDCHT-ULA (grant C-1616-08-08-A) and FONACIT (grant LAB-97000821). The authors thank H.N. de Armas and N. Blaton, Katholieke Universiteit Leuven, Belgium, for data collection.

REFERENCES

- [1] A. Boeijen, J.A. Kruijtzter, R.M. Liskamp, "Combinatorial chemistry of hydantoins", *Bioorg. Med. Chem. Lett.* 8, 2375-2380, 1998.
- [2] K.H. Park, J. Ehrler, H. Spoerri, M.J. Kurth, "Preparation of a 990-member chemical compound library of hydantoin- and isoxazoline-containing heterocycles using multipin technology", *J. Comb. Chem.* 3, 171-176, 2001.
- [3] M.J. Lin, C.M. Sun, "Microwave-assisted traceless synthesis of thiohydantoin", *Tetrahedron Lett.* 44, 8739-8742, 2003.
- [4] W. Zhang, Y.M. Lu, C.H.T. Chen, L. Zeng, D.B. Kassel, "Fluorous mixture synthesis of two libraries with hydantoin-, and benzodiazepinedione-fused heterocyclic scaffolds", *J. Comb. Chem.* 8, 687-695, 2006.
- [5] E. Mutschler, H. Derendorf, "Drug Actions, Basic Principles and Therapeutic Aspects", Medpharm Scientific Publishers, Stuttgart, 1995.
- [6] J. Knabe, J. Baldauf, A. Ahlhem, "Racemates and

- enantiomers of basic substituted 5-phenylhydantoins. Syntheses and antiarrhythmic activity". *Pharmazie*, 52, 912-919, 1997.
- [7] T. Dylag, M. Zygmunt, D. Maciag, J. Handzlik, M. Bednarski, B. Filipek, K. Kiec-Kononowicz, "Synthesis and evaluation of in vivo activity of diphenylhydantoin basic derivatives". *Eur. J. Med. Chem.* 39, 1013-1027, 2004.
- [8] N. Opacic, M. Barbarić, B. Zorc, M. Cetina, A. Nagl, D. Frkovic, M. Kralj, K. Pavelic, J. Balzarini, G. Andrei, R. Snoeck, E. De Clercq, S. Raić-Malić, M. Mintas, "The novel L- and D-Amino acid derivatives of hydroxyurea and hydantoins: Synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations," *J. Med. Chem.* 48, 475-482, 2005.
- [9] E. Lattmann, W.O. Ayuko, D. Kinchinaton, C.A. Langley, H. Singh, L. Karimi, M.J. Tisdale, "Synthesis and evaluation of 5-arylated 2(5H)-furanones and 2-arylated pyridazin-3(2H)-ones as anti-cancer agents", *J. Phar. Pharmacol.* 55, 1259-1265, 2003.
- [10] C. Carmi, A. Cavazzoni, V. Zuliani, A. Lodola, F. Bordi, P.V. Plazzi, R.R. Alfieri, P.G. Petronini, M. Mor, "5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity", *Bioorg. Med. Chem. Lett.* 16, 4021-4025, 2006.
- [11] G. Singh, P.H. Driever, J.W. Sander, L. Sander, "Cancer risk in people with epilepsy: The role of antiepileptic drugs", *Brain* 128, 7-17, 2005.
- [12] A.M. Kaindl, S. Asimiadou, D. Manthey, H.V.D. Hagen, V.D. Turski, C. Ikonomidou, "Antiepileptic drugs and the developing brain", *Cell. Mol. Life Sci.* 63, 399-413, 2006.
- [13] H.H. Merrit, T.J. Putnam, "A new series of anticonvulsant drugs tested by experiments on animals", *Arch. Neurol. Psychiatry* 39, 1003-1015, 1938.
- [14] J.E. Tompkins, "5,5-diaryl-2-thiohydantoins and 5,5-diaryl N3-substituted 2-thiohydantoins as potential hypolipidemic agents", *J. Med. Chem.*, 29, 855-859, 1986.
- [15] A. Takahashi, H. Matsuoka, K. Yamada, Y. Uda, "Characterization of antimutagenic mechanism of 3-allyl-5-substituted 2-thiohydantoins against 2-amino-3-methylimidazo[4,5-f]quinoline", *Food and Chem. Toxicology*, 43, 521-528, 2005.
- [16] S. Al-Madi, A.M. Al-Obaid, H. El-Subbagh, "The in vitro antitumor assay of 5-(Z)-arylidene-4-imidazolidinones in screens of AIDS-related leukemia and lymphomas", *AntiCancer Drugs*, 12, 835-839, 2001.
- [17] M. Shiozaki, "Syntheses of hydantocidin and C-2-thioxohydantocidin", *Carbohydr. Res.* 337, 2077-2088, 2002.
- [18] J. Marton, J. Enisz, S. Hosztafi, T. Timar, "Preparation and fungicidal activity of 5-substituted hydantoins and their 2-thio analogs," *J. Agric. Food. Chem.* 41, 148-152, 1993.
- [19] J. Vázquez, M. Royo, F. Albericio, "Re-evaluation of a solid-phase hydantoin synthesis". *Lett. Org. Chem.* 1, 224-226, 2004.
- [20] Z.D. Wang, S.O. Sheikh, Y.L. Zhang, "A simple synthesis of 2-thiohydantoins", *Molecules*, 11, 739-750, 2006.
- [21] S. Reyes, K. Burgess, "On formation of thiohydantoins from amino acids under acylation conditions". *J. Org. Chem.* 71, 2507-2509, 2006.
- [22] G.E. Delgado, A.J. Mora, J. Uzcátegui, A. Bahsas, A. Briceño, "(S)-5-benzylimidazolidine-2,4-dione monohydrate", *Acta Cryst.* C63, 448-450, 2007.
- [23] G.E. Delgado, L.E. Seijas, A.J. Mora, T. Gonzalez, A. Briceño, "Synthesis, crystal structure and hydrogen-bonding patterns in (RS)-1-carbamoyl pyrrolidine-2-carboxylic acid". *J. Chem. Cryst.* 42, 388-393, 2012.
- [24] G.E. Delgado, L.E. Seijas, A.J. Mora, "Synthesis and crystal structure determination of hydantoin-L-proline". *J. Chem. Cryst.* 2012. DOI 10.1007/s10870-012-0344-3.
- [25] L.E. Seijas, G. E. Delgado, A.J. Mora, A. Bahsas, J. Uzcátegui, "Síntesis y caracterización de los derivados N-carbamoilo e hidantoína de L-prolina", *Av. Quím.* 1, 3-7, 2006.
- [26] L.E. Seijas, G. E. Delgado, A.J. Mora, A. Bahsas, A. Briceño, "(2S)-1-carbamoyl pyrrolidine-2-carboxylic acid", *Acta Cryst.* C63, o303-o305, 2007.
- [27] L.E. Seijas, A.J. Mora, G.E. Delgado, M. Brunelli, A.N. Fitch, "Study of the conversion of N-carbamoyl-L-proline to hydantoin-L-proline using powder synchrotron X-ray diffraction", *Powder Diffr.* 25, 342-348, 2010.
- [28] M.E. Sulbaran, G.E. Delgado, A.J. Mora, A. Bahsas, H. Novoa de Armas, N. Blaton. "Hydrogen-bonding patterns in rac-1-acetyl-5-methyl-2-thioxoimidazolidine-4-one". *Acta Cryst.* C63, o543-o545, 2007.
- [29] X-ray Single Crystal Analysis System (XSCANS), Version 2.2; Siemens Analytical X-ray Instruments Inc.: Madison, WI, USA, 1996.
- [30] G.M. Sheldrick, "A short history of SHELX", *Acta Cryst.* A64, 112-122, 2008.
- [31] G. Bergerhoff, M. Berndt, K. Brandenburg, "Evaluation of Crystallographic Data with the Program DIAMOND", *J. Res. Natl. Inst. Stand. Technol.* 101, 221-225, 1996.
- [32] A.L. Spek, "Single-crystal structure validation with the program Platon", *J. Appl. Cryst.* 36, 7-13, 2003.
- [33] R. Yoshioka, "Racemization, optical resolution and crystallization-induced asymmetric transformation of amino acids and pharmaceutical intermediates". *Top. Curr. Chem.* 269, 83-132, 2007.
- [34] F.H. Allen, "The cambridge structural database: a quarter of a million crystal structures and rising", *Acta Cryst.* B58, 380-388, 2002.
- [35] M.F. Mackay, B.M. Duggan, R.L. Laslett, J.F.K. Wilshire, "Structure of a substituted 2-thiohydantoin", *Acta Cryst.* C48, 334-336, 1992.
- [36] J.S. Casas, A. Castañeiras, D. Couce, N. Playá, J. Sordo, J.M. Varela, "1-acetyl-2-thiohydantoin", *Acta Cryst.* C54, 427-428, 1998.
- [37] M.C. Etter, "Encoding and decoding hydrogen-bond patterns of organic-compounds" *Acc. Chem. Res.* 23, 120-126, 1990.